TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02240069

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education (Tx1)
Description: Education on best burn practices

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Air Filtration Unit Treatment (Tx2)
Description: A 20 x 18 Filtrete air filtration unit (3M, St. Paul, MN) will be placed in the same room as the wood stove

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Placebo Intervention (Tx3)
Description: A 20 x 18 Filtrete air filtration unit will be installed within the wood stove home. Instead of a high efficiency filter, the units will utilize a placebo filter.
Study: NCT03228316

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: superior hypogastric plexus block
Description: nerve plexus block

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: superior hypogastric plexus block
Description: nerve plexus block

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: pulsed radiofrequency
Description: pulsed radiofrequency on sacral nerve roots 2,3 and 4
Study: NCT02387528

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 1- Mindfulness Intervention
Description: An intervention program integrating elements of Mindfulness Breathworks Institute Mindfulness based approaches for Pain and illness (MBPI), (Burch , 2009) and Mindfulness Based Stress Reduction (MBSR), (Kabat Zinn, 2003), and Mindfulness based Cognitive Therapy (MBCT) shall be used. All programs are highly structured, lasting eight weeks, with a weekly meeting about two hours , and working with four main techniques during these meetings : mindfulness in breathing, body scan, walking meditation and mindfulness yoga. In order to facilitate the home practice of meditation by participants during and after the intervention protocol, all will receive a CD containing guided meditation sessions, covering the above techniques.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: 2- Relaxation Intervention
Description: Eight meetings where the participants will practice relaxation techniques.

Intervention type: OTHER
Group type: OTHER
Intervention: 3- Wait List Control Group
Description: No intervention
Study: NCT01848743

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: lamivudine
Study: NCT01883947

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Touch massage
Description: Touch massage is a gentle massage with strokes on hands, arms, feet and legs with at pressure of 2.5 N which is more gentle than Swedish massage but harder than strokes performed with a brush. The speed of the strokes is about 1-5 cm/sec. During the massage, the subjects will lie on a bed. Intervention group will receive touch massage on hands and feet and the intervention will start one week after the onset of stroke and last for 30 minutes each time, five days a week for two weeks

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: non-TENS
Description: Subjects in the control group will have sham treatment which is a non-active transcutaneous electrical nerve stimulation (non-TENS), while they lie in bed with electrodes attached to the skin of the affected arm. The device will be manipulated in a way so that no electrical impulses will reach the electrodes. During treatment, the masseur will remain in the room without initiating any conversation.
Study: NCT01447927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin hydrochloride
Description: Given PO QD and BID

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO QD and BID
Study: NCT02468128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sebacoyl Dinalbuphine Ester
Description: Intramuscular injection 2mL/vial (75mg/mL)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sebacoyl Dinalbuphine Ester injection placebo, 2mL/vial
Study: NCT00640653

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Abstinence-only HIV/STD risk-reduction intervention
Description: Participants will attend two sessions consisting of eight 1-hour modules that are designed to increase knowledge, motivation, and skill for practicing abstinence. The intervention is not an abstinence-until-marriage intervention; the target behavior is abstaining from sexual activity until later in life when the adolescent is more prepared to handle the consequences. The intervention does not contain inaccurate information, portray sex in a negative light, or employ a moralistic tone. It is not designed to affect condom use.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safer-sex-only HIV/STD risk-reduction intervention
Description: Participants will attend two sessions consisting of eight 1-hour modules that are designed to increase knowledge, motivation, and skill for using condoms during sexual intercourse. The intervention is not designed to influence abstinence.
Study: NCT00078858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Given PO or IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00640653

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Long comprehensive HIV/STD risk-reduction intervention
Description: Participants will attend three sessions consisting of twelve 1-hour modules that are designed to increase knowledge, motivation, and skill for practicing abstinence and for using condoms if participants decide to be sexually active. The intervention consists of the safer-sex-specific content (4 hours), the abstinence-specific content (4 hours), and the general content that is common to both of the single-component interventions (4 hours).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Short comprehensive HIV/STD risk-reduction intervention
Description: Participants will attend two sessions consisting of eight 1-hour modules that are designed to increase knowledge, motivation, and skill for practicing abstinence and for using condoms if participants decide to be sexually active.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health promotion control intervention
Description: Participants will attend two sessions consisting of eight 1-hour modules that are designed to increase knowledge, motivation, and skill for avoiding cigarette smoking and for incorporating a healthful diet, aerobic exercise, and breast and testicular self-examinations. The control intervention will focus on reducing risk of heart disease, hypertension, diabetes, and certain cancers. The intervention provides a control for Hawthorne effects to reduce the likelihood that the HIV/STD interventions' effects can be attributed to group interaction and special attention.
Study: NCT03644836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amino Acids
Description: Sweet taste cocoa flavored drink

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Sweet taste cocoa flavored drink
Study: NCT03482791

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton beam therapy
Description: * The daily prescription dose will be 1.8 or 2 Gy RBE (Relative Biologic Equivalence) to be delivered to the periphery of the planning target volume (PTV).~* The Mevion S-250 Proton Radiation Beam Therapy System will be used.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton beam therapy
Description: * The daily prescription dose will be 1.8 or 2 Gy RBE (Relative Biologic Equivalence) to be delivered to the periphery of the planning target volume (PTV).~* The Mevion S-250 Proton Radiation Beam Therapy System will be used.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient-Reported Outcome Measures
Description: -Prior to start of therapy, end of chemoradiation (day of end of treatment or up to 1 week after), 8 weeks, 4, 6, 9, and 12-months following end of chemoradiation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient-Reported Outcome Measures
Description: -Prior to start of therapy, end of chemoradiation (day of end of treatment or up to 1 week after), 8 weeks, 4, 6, 9, and 12-months following end of chemoradiation
Study: NCT04608344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Administered as single dose tablet orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Administered as single dose tablet orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin
Description: Administered as single dose tablet orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin
Description: Administered as single dose tablet orally.
Study: NCT04596241

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BTL-899
Description: Treatment with intensities of a magnetic field and radiofrequency energy just below the patient's tolerance threshold.
Study: NCT01861795

Intervention type: OTHER
Intervention: Preterm Neonates
Description: Preterm Neonates
Study: NCT03936075

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: the Guided Imagery and Music method
Description: the method involves listening to the music while describing the experience to the therapist, any visual imagery that is evoked by the music, emotions, body sensations, thoughts or memories. after the music listening session, there is discussion upon making meaning of the experience and finding resources as potential coping skills

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: standard care and verbal counselling
Description: the participants receive their usual cancer treatment and two individual counselling sessions
Study: NCT03277417

Intervention type: OTHER
Intervention: Echocardiography
Description: Imaging of fetal heart and amniotic fluid

Intervention type: OTHER
Intervention: Echocardiography
Description: Imaging of fetal heart and amniotic fluid

Intervention type: OTHER
Intervention: Echocardiography
Description: Imaging of fetal heart and amniotic fluid
Study: NCT03877952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C-CORT125281
Description: 14C-CORT125281 360 mg capsule for oral administration containing not more than 2.5 megaBequerel (67 μCi) 14C
Study: NCT01747837

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Boston Scientific Vessix Renal Denervation System
Description: Renal sympathetic denervation is modulation of the nerves which run along the renal arteries (the renal sympathetic nerves) with radiofrequency energy. This is the same energy source used to perform your heart ablation.~Boston Scientific Vessix Renal Denervation System, Boston Scientific, Inc., Quincy, Massachusetts
Study: NCT04608344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Administered as single dose tablet orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Administered as single dose tablet orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: Administered as tablet orally once daily for 11 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: Administered as tablet orally once daily for 11 days.
Study: NCT02103335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pomalidomide
Description: Oral Pomalidomide, days 1-21 of 28 day cycle, dose 3 to 4 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: marizomib
Description: IV Marizomib, 0.2 to 0.5 mg/m2 on days 1, 4, 8, 11 of 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low-dose dexamethasone
Description: Oral Dexamethasone, days 1, 2, 4, 5, 8, 9, 11, 12, 15, 16, 22, 23 of 28 day cycle, 5 or 10 mg
Study: NCT03660475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: naltrexone formulated as ophthalmic solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo ophthalmic solution
Study: NCT00232596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retigabine
Description: Oral tablet. The starting daily dose will be 300 mg/day administered orally in three equally divided doses. This dosage will be increased by 150 mg/day (50 mg/dose) at 1-week intervals (titration phase). At the beginning of Week 7, patients will enter a 12 week maintenance phase

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet.
Study: NCT01238562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YPEG-Filgrastim
Description: s.c, single dose of 10mcg/kg of YPEG-Filgrastim at 48hr of cycle 2, followed by daily s.c either 2.5 mcg/kg or 5 mcg/kg of filgrastim(TOPNEUTER) starting from 48hr of cycle 3 until WBC≥10,000 per cubic milliliter or ANC≥5,000 per cubic milliliter in two continuous daily tests after ANC nadir.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YPEG-Filgrastim
Description: s.c, single dose of 20mcg/kg of YPEG-Filgrastim at 48hr of cycle 2, followed by daily s.c either 2.5 mcg/kg or 5 mcg/kg of filgrastim(TOPNEUTER) starting from 48hr of cycle 3 until WBC≥10,000 per cubic milliliter or ANC≥5,000 per cubic milliliter in two continuous daily tests after ANC nadir.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YPEG-Filgrastim
Description: s.c, single dose of 30mcg/kg of YPEG-Filgrastim at 48hr of cycle 2, followed by daily s.c either 2.5 mcg/kg or 5 mcg/kg of filgrastim(TOPNEUTER) starting from 48hr of cycle 3 until WBC≥10,000 per cubic milliliter or ANC≥5,000 per cubic milliliter in two continuous daily tests after ANC nadir.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YPEG-Filgrastim
Description: s.c, single dose of 45mcg/kg of YPEG-Filgrastim at 48hr of cycle 2, followed by daily s.c either 2.5 mcg/kg or 5 mcg/kg of filgrastim(TOPNEUTER) starting from 48hr of cycle 3 until WBC≥10,000 per cubic milliliter or ANC≥5,000 per cubic milliliter in two continuous daily tests after ANC nadir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YPEG-Filgrastim
Description: s.c, single dose of 60mcg/kg of YPEG-Filgrastim at 48hr of cycle 2, followed by daily s.c either 2.5 mcg/kg or 5 mcg/kg of filgrastim(TOPNEUTER) starting from 48hr of cycle 3 until WBC≥10,000 per cubic milliliter or ANC≥5,000 per cubic milliliter in two continuous daily tests after ANC nadir.
Study: NCT02089100

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiation therapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Systemic treatment

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Systemic treatment
Study: NCT03525028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: The investigators assumed that the combination therapy of metformin and glucocorticoids can decrease glucocorticoids side effects and synergia the anti-inflammatory and immune inhibitory effect of glucocorticoids. So the investigators use metformin in the experimental group.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The investigators use placebo in the control group.
Study: NCT02523235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine 0.2%
Description: Perineural ropivacaine 0.2% at 8 mL/h (adductor) or 6 mL/h (popliteal) basal rate infusion and a 4 mL patient-controlled bolus with a 30 minute lockout

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine 0.2%
Description: Perineural ropivacaine 0.2% at 8 mL/h (adductor) or 6 mL/h (popliteal) basal rate infusion and a 4 mL patient-controlled bolus with a 30 minute lockout
Study: NCT02968667

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empowerment
Description: 6 weeks of empowerment program and supported face to face discussion
Study: NCT00911209

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietitian counselling
Description: Once a week for 14 weeks then 1 monthly visit. Visits last 40-50 minutes
Study: NCT02948010

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Auto CPAP + comfort feature A
Description: Auto CPAP + comfort feature A using Fisher \& Paykel Healthcare CPAP Device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Auto CPAP with comfort feature B
Description: Auto CPAP with comfort feature B using Fisher \& Paykel Healthcare CPAP Device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Auto CPAP with no comfort feature
Description: Auto CPAP with no comfort feature using Fisher \& Paykel Healthcare CPAP Device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Auto CPAP with comfort feature A+B
Description: Auto CPAP with comfort feature A+B using Fisher \& Paykel Healthcare CPAP Device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP with comfort feature A
Description: CPAP with comfort feature A using Fisher \& Paykel Healthcare CPAP Device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP with comfort feature B
Description: CPAP with comfort feature B using Fisher \& Paykel Healthcare CPAP Device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP with no comfort feature
Description: CPAP with no comfort feature using Fisher \& Paykel Healthcare CPAP Device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP with comfort feature A + B
Description: CPAP with comfort feature A + B using Fisher \& Paykel Healthcare CPAP Device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP at Sub therapeutic level
Description: CPAP at Sub therapeutic level using Fisher \& Paykel Healthcare CPAP Device
Study: NCT03308318

Intervention type: PROCEDURE
Intervention: The supratemporalis approach
Description: The incision differs according to specific fracture sites. It can be a hockey stick-shaped incision, hemicoronal incision, and full coronal incision. The first layer of dissection was just under the superficial temporalis fascia.Then, approximately at the level of 3-5cm above the zygomatic arch, our modified incision was carried through the deep temporalis fascia.Next, the superficial fat pad was encountered and retracted anteriorly, which was in close contact of the temporal muscle. Finally, a flap that included skin, subcutaneous tissue, the superficial temporal fascia, the areolar fat tissue, the deep temporalis fascia and the superficial temporal fat was reflected as a whole anteriorly, fully exposing the temporal muscle and zygomatic arch.
Study: NCT02543892

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PATH-wSP
Description: Streptococcus pneumoniae Whole Cell Vaccine, Inactivated and Adsorbed to Aluminum Hydroxide

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PATH-wSP
Description: Streptococcus pneumoniae Whole Cell Vaccine, Inactivated and Adsorbed to Aluminum Hydroxide

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PATH-wSP
Description: Streptococcus pneumoniae Whole Cell Vaccine, Inactivated and Adsorbed to Aluminum Hydroxide

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PATH-wSP
Description: Streptococcus pneumoniae Whole Cell Vaccine, Inactivated and Adsorbed to Aluminum Hydroxide

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline
Study: NCT00633776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: formoterol fumarate
Description: Nebulized formoterol fumarate 20 mcg one-time treatment; aerosolizer dry powder formoterol fumarate 12 mcg one-time treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: formoterol fumarate
Description: Nebulized formoterol fumarate 20 mcg one-time treatment; aerosolizer dry powder formoterol fumarate 12 mcg one-time treatment
Study: NCT01484093

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: R-CHOP-14R-HIDAC,followed by RIT/HDT/ASCR.
Description: INDUCTION: R-CHOP-14 CHEMOTHERAPY: 4 cycles every 2 weeks ± 1 day All patients in the study in both phases will undergo induction and consolidation with R-CHOP 14R-HIDAC, followed by RIT/HDT/ASCR. Patients will undergo restaging scans 12 to 14 days following completion of R-CHOP 14, with CT, and FDG-PET. Patients demonstrating at least a PR may proceed to consolidation with R-HIDAC. CONSOLIDATION: R- HIDAC CHEMOTHERAPY: 2 cycles every 3 weeks ± 2 days After R-HIDAC, restaging will occur 17-21 days post cycle 2 with CT scan (or FDG-PET, if this was positive following R-CHOP-14). Radioimmunotherapy Dosimetric dose is given approximately 4-5 weeks after completing cycle 2 of R-HIDAC. This is to be preferred 1 week post restaging scans 17-21 days post cycle 2 of RHIDAC, and up to 2 weeks post-scans will be acceptable only if required by 131 I Tositumomab availability.
Study: NCT03772977

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brain Health Champion
Description: A health coach embedded within an existing clinical care team
Study: NCT03764228

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hAECs
Description: Human amniotic epithelial cells（hAECs）
Study: NCT01707251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Ibuprofen
Description: 800 mg Ibuprofen IV every 6 hours starting preoperatively (5 doses).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Placebo control
Study: NCT03315988

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adoption of a vegan diet
Description: Adoption of a vegan diet The participants of this study wil be asked to adopt a vegan diet under the supervision of a Registered Dietitian.
Study: NCT05452837

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FDFG
Description: FDFG is applied to the parotidectomy bed after superficial parotidectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SMAS
Description: SMAS flap is applied to the parotidectomy bed after superficial parotidectomy
Study: NCT00387907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: larotaxel (XRP9881)
Description: administered as a 1-hour IV infusion on Day 1 of every 3 weeks (q3w)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: administered as a 90-minute IV infusion on Day 1 of every week (qw)
Study: NCT02811393

Intervention type: OTHER
Intervention: Assess muscle function
Description: Assess muscle function with hand grip test and sit and stand test

Intervention type: OTHER
Intervention: Assess muscle function
Description: Assess muscle function with hand grip test and sit and stand test